SlideShare a Scribd company logo
1 of 8
INFOSYS LIMITED 
Balance Sheet as at March 31, Note EQUITY AND LIABILITIES 
SHAREHOLDERS' FUNDS 
Share capital 2.1 Reserves and surplus 2.2 
NON-CURRENT LIABILITIES 
Deferred tax liabilities (net) 2.3 Other long-term liabilities 2.4 
CURRENT LIABILITIES 
Trade payables 2.5 Other current liabilities 2.6 Short-term provisions 2.7 
ASSETS NON-CURRENT ASSETS Fixed assets 
Tangible assets 2.8 Intangible assets 2.8 Capital work-in-progress 
Non-current investments 2.10 Deferred tax assets (net) 2.3 Long-term loans and advances 2.11 Other non-current assets 2.12 
CURRENT ASSETS 
Current investments 2.10 Trade receivables 2.13 Cash and cash equivalents 2.14 Short-term loans and advances 2.15 
SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS 1 & 2 
2013 
287 35,772 36,059 
56 120 176 
178 2,827 3,788 6,793 
43,028 
4,425 28 1,135 5,588 
2,764 378 1,529 31 10,290 
1,580 
6,365 20,401 4,392 32,738 
43,028 
in ` crore 2012 
287 29,470 29,757 
- 21 
21 
68 2,365 3,604 6,037 
35,815 
4,045 16 588 4,649
1,068 189 1,431 13 7,350 
341 5,404 19,557 3,163 28,465 
35,815 
Deepak M. Satwalekar 
Director 
R.Seshasayee 
Director 
V. Balakrishnan 
Director 
N.R. Ravikrishnan 
Company Secretary 
As per our report at tached 
for BSR&Co. 
Chartered Accountants 
Firm's Regist rat ion Number:101248W 
Nat rajh Ramakrishna 
Partner 
Membership No. 32815 
K.V.Kamath 
Chairman 
Dr. Omkar Goswami 
Director 
Ann M. Fudge 
Director 
Ashok Vemuri 
Director 
S. Gopalakrishnan 
Execut ive Co-Chairman 
David L. Boyles 
Director 
Ravi Venkatesan 
Director
B. G. Srinivas 
Director 
S. D. Shibulal 
Bangalore April 12, 2013 
Chief Execut ive Officer and Managing Director 
Prof. Jeffrey S. Lehman 
Director 
Srinath Batni 
Director 
Rajiv Bansal 
Chief Financial Officer 
1 
INFOSYS LIMITED 
Statement of Profit and Loss for the 
Income from software services and products Other income 
Total revenue 
Expenses 
Employee benefit expenses 
Deferred consideration pertaining to acquisit ion 
Cost of technical sub-contractors 
Travel expenses 
Cost of software packages and others 
Communication expenses 
Professional charges 
Depreciation and amortisation expense 
Other expenses 
Total expenses 
PROFIT BEFORE EXCEPTIONAL ITEM AND TAX Dividend income 
PROFIT BEFORE TAX 
Tax expense: 
Current tax 
Deferred tax 
PROFIT FOR THE PERIOD 
EARNINGS PER EQUITY SHARE 
Equity shares of par value `5/- each Before Exceptional item 
Basic Diluted 
After Exceptional item Basic 
Diluted
Number of shares used in comput ing earnings per share 
Basic Diluted 
SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS 
As per our report at tached 
for BSR&Co. 
Chartered Accountants 
Firm's Regist rat ion Number : 101248W 
Note 
2.16 2.17 
2.18 2.10.1 2.18 2.18 2.18 2.18 
2.8 2.18 
2.36 
2.19 2.19 
in ` crore, except per share data Quarter ended March 31, Year ended March 31, 
2013 
9,329 647 9,976 
5,199 50 524 270 182 70 117 256 286 6,954 3,022 
- 
3,022 
738 (21) 
2,305 
40.14 40.14 
40.14 40.14 
2012 2013 
2012 
31,254 1,829 33,083 
15,473 - 2,483 
944 625 203 437 794 
1,028 
21,987 11,096 578 11,674 
3,147 57 8,470 
139.07 139.06
147.51 147.50 
8,183 609 8,792 
4,051 - 
656 231 182 
53 
85 204 219 5,681 3,111 578 3,689 
909 21 2,759 
39.61 39.61 
48.05 48.05 
36,765 2,215 38,980 
19,932 85 1,731 1,281 734 289 504 956 1,194 26,706 12,274 83 12,357 
3,361 (120) 
9,116 
157.55 157.55 
158.76 158.76 
2.31 
1&2 
S. Gopalakrishnan 
Execut ive Co-Chairman 
David L. Boyles 
Director 
Ravi Venkatesan 
Director 
B. G. Srinivas 
Director 
57,42,36,166 57,42,25,771 57,42,32,838 57,41,99,094 57,42,36,166 57,42,33,173 57,42,33,691 57,42,29,742 
Nat rajh Ramakrishna 
Partner 
Membership No. 32815 
K.V.Kamath
Chairman 
Dr. Omkar Goswami 
Director 
Ann M. Fudge 
Director 
Ashok Vemuri 
Director 
S. D. Shibulal 
Chief Execut ive Officer and Managing Director 
Prof. Jeffrey S. Lehman 
Director 
Srinath Batni 
Director 
Rajiv Bansal 
Chief Financial Officer 
Deepak M. Satwalekar 
Director 
R.Seshasayee 
Director 
V. Balakrishnan 
Director 
N.R. Ravikrishnan 
Company Secretary 
Bangalore April 12, 2013 
2 
INFOSYS LIMITED 
Cash Flow Statement for the 
CASH FLOWS FROM OPERATING ACTIVITIES 
Profit before tax and exceptional item 
Adjustments to reconcile profit before tax to cash provided by operating activities 
Depreciation and amortisation expense 
Payable for acquisition of business 
Interest and dividend income 
Loss/(Profit) on sale of tangible assets 
Effect of exchange differences on translation of assets and liabilities Effect of exchange differences on translation of foreign currency cash and cash equivalents
Changes in assets and liabilities Trade receivables 
Loans and advances and other assets Liabilities and provisions 
Income taxes paid 
NET CASH GENERATED BY OPERATING ACTIVITIES 
CASH FLOWS FROM INVESTING ACTIVITIES 
Payment towards capital expenditure 
Investments in subsidiaries 
Investment in other investments 
Disposal of other investments 
Interest and dividend received 
CASH FLOWS FROM INVESTING ACTIVITIES BEFORE EXCEPTIONAL ITEM Dividend received 
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES 
CASH FLOWS FROM FINANCING ACTIVITIES 
Proceeds from issuance of share capital on exercise of stock options Loan given to subsidiary 
Dividends paid including residual dividend 
Dividend tax paid 
NET CASH USED IN FINANCING ACTIVITIES 
Effect of exchange differences on translation of foreign currency cash and cash equivalents 
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS 
Add: Bank balances taken over from Infosys Consulting Inc., USA (refer to note 2.25) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 
SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS 
Note 
Year ended March 31, 2013 
12,274 
956 85 (1,931) 
- 15 
(45) 
(961) (997) 690 
10,086 (3,144) 6,942 
(1,847) (1,384) (1,883) 
336 1,871 (2,907) 83 
(2,824) 
1 (184) (2,698) (438) (3,319) 
45 
844 
- 19,557 20,401 
in ` crore 2012 
11,096
794 - 
(1,720) (2) 19 
(60) 
(1,180) (819) 671 
8,799 (2,938) 5,861 
(1,296) (104) (2,796) 
2,574 1,703 81 578 659 
6 35 (2,012) (327) 
(2,298) 
60 
4,282 
110 15,165 19,557 
As per our report attached 
for BSR&Co. 
Chartered Accountants 
Firm's Registration Number : 101248W 
2.35.1 2.35.2 2.35.3 
2.35.4 
2.35.5 2.35.6 2.35.7 2.35.7 2.35.8 
2.36 
2.35.9 
1 & 2

More Related Content

What's hot

1803 hcc consol_eng_signed
1803 hcc consol_eng_signed1803 hcc consol_eng_signed
1803 hcc consol_eng_signedHyundai Finance
 
캐피탈 영문보고서
캐피탈 영문보고서캐피탈 영문보고서
캐피탈 영문보고서Hyundai Finance
 
4 q18 hcc_presentation_web_eng_190326
4 q18 hcc_presentation_web_eng_1903264 q18 hcc_presentation_web_eng_190326
4 q18 hcc_presentation_web_eng_190326Hyundai Finance
 
Conference Call 4Q13
Conference Call 4Q13Conference Call 4Q13
Conference Call 4Q13ItauRI
 
Zenith bank annual report 2016
Zenith bank annual report 2016Zenith bank annual report 2016
Zenith bank annual report 2016Michael Olafusi
 
ABC holdings preliminary results
ABC holdings preliminary resultsABC holdings preliminary results
ABC holdings preliminary resultswgjlubbe
 
캐피탈 영문 감사보고서
캐피탈 영문 감사보고서캐피탈 영문 감사보고서
캐피탈 영문 감사보고서Hyundai Finance
 
Banco ABC - 1st Quarter 2008 Results Presentation
Banco ABC - 1st Quarter 2008 Results PresentationBanco ABC - 1st Quarter 2008 Results Presentation
Banco ABC - 1st Quarter 2008 Results PresentationBanco ABC Brasil
 
Zenith Bank Annual Report 2013
Zenith Bank Annual Report 2013Zenith Bank Annual Report 2013
Zenith Bank Annual Report 2013Michael Olafusi
 
Hyundai card opinion_con_2017_2q_최종signed
Hyundai card opinion_con_2017_2q_최종signedHyundai card opinion_con_2017_2q_최종signed
Hyundai card opinion_con_2017_2q_최종signedHyundai Finance
 
2 q17 hcc_presentation_eng_web_vf
2 q17 hcc_presentation_eng_web_vf2 q17 hcc_presentation_eng_web_vf
2 q17 hcc_presentation_eng_web_vfHyundai Finance
 
2013년 3분기 검토보고서 en
2013년 3분기 검토보고서 en2013년 3분기 검토보고서 en
2013년 3분기 검토보고서 enHyundai Finance
 
Ccal 3 q12_ing
Ccal 3 q12_ingCcal 3 q12_ing
Ccal 3 q12_ingItauRI
 
Golar LNG Partners Q1 2013 results presentation
Golar LNG Partners Q1 2013 results presentationGolar LNG Partners Q1 2013 results presentation
Golar LNG Partners Q1 2013 results presentationTradeWindsnews
 

What's hot (20)

1803 hcc consol_eng_signed
1803 hcc consol_eng_signed1803 hcc consol_eng_signed
1803 hcc consol_eng_signed
 
캐피탈 영문보고서
캐피탈 영문보고서캐피탈 영문보고서
캐피탈 영문보고서
 
4 q18 hcc_presentation_web_eng_190326
4 q18 hcc_presentation_web_eng_1903264 q18 hcc_presentation_web_eng_190326
4 q18 hcc_presentation_web_eng_190326
 
3q15hccauditeng
3q15hccauditeng3q15hccauditeng
3q15hccauditeng
 
UBA Annual Report 2017
UBA Annual Report 2017UBA Annual Report 2017
UBA Annual Report 2017
 
Sa fy13-q4-finstatement
Sa fy13-q4-finstatementSa fy13-q4-finstatement
Sa fy13-q4-finstatement
 
Conference Call 4Q13
Conference Call 4Q13Conference Call 4Q13
Conference Call 4Q13
 
Bhavna
BhavnaBhavna
Bhavna
 
Zenith bank annual report 2016
Zenith bank annual report 2016Zenith bank annual report 2016
Zenith bank annual report 2016
 
ABC holdings preliminary results
ABC holdings preliminary resultsABC holdings preliminary results
ABC holdings preliminary results
 
캐피탈 영문 감사보고서
캐피탈 영문 감사보고서캐피탈 영문 감사보고서
캐피탈 영문 감사보고서
 
Banco ABC - 1st Quarter 2008 Results Presentation
Banco ABC - 1st Quarter 2008 Results PresentationBanco ABC - 1st Quarter 2008 Results Presentation
Banco ABC - 1st Quarter 2008 Results Presentation
 
Zenith Bank Annual Report 2013
Zenith Bank Annual Report 2013Zenith Bank Annual Report 2013
Zenith Bank Annual Report 2013
 
Hyundai card opinion_con_2017_2q_최종signed
Hyundai card opinion_con_2017_2q_최종signedHyundai card opinion_con_2017_2q_최종signed
Hyundai card opinion_con_2017_2q_최종signed
 
Hcc 2 q_eng
Hcc 2 q_engHcc 2 q_eng
Hcc 2 q_eng
 
2 q17 hcc_presentation_eng_web_vf
2 q17 hcc_presentation_eng_web_vf2 q17 hcc_presentation_eng_web_vf
2 q17 hcc_presentation_eng_web_vf
 
2013년 3분기 검토보고서 en
2013년 3분기 검토보고서 en2013년 3분기 검토보고서 en
2013년 3분기 검토보고서 en
 
Hcc 3 q_eng
Hcc 3 q_engHcc 3 q_eng
Hcc 3 q_eng
 
Ccal 3 q12_ing
Ccal 3 q12_ingCcal 3 q12_ing
Ccal 3 q12_ing
 
Golar LNG Partners Q1 2013 results presentation
Golar LNG Partners Q1 2013 results presentationGolar LNG Partners Q1 2013 results presentation
Golar LNG Partners Q1 2013 results presentation
 

Viewers also liked

Benefits of homeopathy
Benefits of homeopathyBenefits of homeopathy
Benefits of homeopathyDrKavita S
 
APWA Stormwater Presentation_01.09.12
APWA Stormwater Presentation_01.09.12APWA Stormwater Presentation_01.09.12
APWA Stormwater Presentation_01.09.12apwacoachellavalley
 
Updates in management_of_malignant_pleural_mesothelioma
Updates in management_of_malignant_pleural_mesotheliomaUpdates in management_of_malignant_pleural_mesothelioma
Updates in management_of_malignant_pleural_mesotheliomaMoustapha Mounib
 
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...Mesothelioma Applied Research Foundation
 
Crs+hipec— jeddah,
Crs+hipec— jeddah,Crs+hipec— jeddah,
Crs+hipec— jeddah,Basalama Ali
 
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...Mesothelioma Applied Research Foundation
 
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...Mesothelioma Applied Research Foundation
 
Mesothelioma Lawsuits Guide
Mesothelioma Lawsuits GuideMesothelioma Lawsuits Guide
Mesothelioma Lawsuits GuideAnapol Weiss
 
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...The Mesothelioma Center at Asbestos.com
 
Homeopathy therapy for mesothelioma treatment
Homeopathy therapy for mesothelioma treatmentHomeopathy therapy for mesothelioma treatment
Homeopathy therapy for mesothelioma treatmentTanzil Al Gazmir
 
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...Mesothelioma Applied Research Foundation
 
Mesothelioma presentation
Mesothelioma presentationMesothelioma presentation
Mesothelioma presentationMiranda Shop
 
Pleural Mesothelioma - Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku JosephPleural Mesothelioma - Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku JosephDr.Tinku Joseph
 
Complementary and alternative medicine
Complementary and alternative medicineComplementary and alternative medicine
Complementary and alternative medicinesunil chhajwani
 

Viewers also liked (18)

Medical Side of Depression and Mesothelioma
Medical Side of Depression and MesotheliomaMedical Side of Depression and Mesothelioma
Medical Side of Depression and Mesothelioma
 
Benefits of homeopathy
Benefits of homeopathyBenefits of homeopathy
Benefits of homeopathy
 
Denak
DenakDenak
Denak
 
Quotes
QuotesQuotes
Quotes
 
APWA Stormwater Presentation_01.09.12
APWA Stormwater Presentation_01.09.12APWA Stormwater Presentation_01.09.12
APWA Stormwater Presentation_01.09.12
 
Updates in management_of_malignant_pleural_mesothelioma
Updates in management_of_malignant_pleural_mesotheliomaUpdates in management_of_malignant_pleural_mesothelioma
Updates in management_of_malignant_pleural_mesothelioma
 
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...
Occupational and 9/11 Exposures and Cancer Risk | Mesothelioma Applied Resear...
 
Crs+hipec— jeddah,
Crs+hipec— jeddah,Crs+hipec— jeddah,
Crs+hipec— jeddah,
 
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...
Peritoneal Surgery and Intraperitoneal Chemotherapy | Mesothelioma Applied Re...
 
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...
The Role of Surgery in Malignant Pleural Mesothelioma | Mesothelioma Applied ...
 
Mesothelioma Lawsuits Guide
Mesothelioma Lawsuits GuideMesothelioma Lawsuits Guide
Mesothelioma Lawsuits Guide
 
Peritoneal carcinomatosis
Peritoneal carcinomatosisPeritoneal carcinomatosis
Peritoneal carcinomatosis
 
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...
The Mesothelioma Center's March 2015 Support Group - Complementary and Altern...
 
Homeopathy therapy for mesothelioma treatment
Homeopathy therapy for mesothelioma treatmentHomeopathy therapy for mesothelioma treatment
Homeopathy therapy for mesothelioma treatment
 
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...
Chemotherapy for Advanced Peritoneal Mesothelioma | Mesothelioma Applied Rese...
 
Mesothelioma presentation
Mesothelioma presentationMesothelioma presentation
Mesothelioma presentation
 
Pleural Mesothelioma - Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku JosephPleural Mesothelioma - Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku Joseph
 
Complementary and alternative medicine
Complementary and alternative medicineComplementary and alternative medicine
Complementary and alternative medicine
 

Similar to Accounts

Sa fy12-annual-finstatement12
Sa fy12-annual-finstatement12Sa fy12-annual-finstatement12
Sa fy12-annual-finstatement12Anjaneyulu Bandi
 
Zenith bank annual report 2018
Zenith bank annual report 2018Zenith bank annual report 2018
Zenith bank annual report 2018Michael Olafusi
 
Review reports 1 q2017 en
Review reports 1 q2017 enReview reports 1 q2017 en
Review reports 1 q2017 enHyundai Finance
 
Zenith bank annual report 2015
Zenith bank annual report 2015Zenith bank annual report 2015
Zenith bank annual report 2015Michael Olafusi
 
PLDT Financial Statements (2013-2015)
PLDT Financial Statements (2013-2015)PLDT Financial Statements (2013-2015)
PLDT Financial Statements (2013-2015)Carll Angelo Conje
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherIndiaNotes.com
 
2016 영문 감사보고서 en
2016 영문 감사보고서  en2016 영문 감사보고서  en
2016 영문 감사보고서 enHyundai Finance
 
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...Ke Zheng
 
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docx
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docxCONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docx
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docxbobbywlane695641
 
캐 재무제표 2015_영
캐 재무제표 2015_영캐 재무제표 2015_영
캐 재무제표 2015_영Hyundai Finance
 
1Q21_Audit_EN.pdf
1Q21_Audit_EN.pdf1Q21_Audit_EN.pdf
1Q21_Audit_EN.pdfirhcs
 
2016년 1분기 검토보고서 en
2016년 1분기 검토보고서  en2016년 1분기 검토보고서  en
2016년 1분기 검토보고서 enHyundai Finance
 
Consolidate december-2012
Consolidate december-2012Consolidate december-2012
Consolidate december-2012Afridi Khy
 
2016 audited financials
2016 audited financials2016 audited financials
2016 audited financials~Eric Principe
 
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis  FY 2013 FY 2014 FY 2015 .docxStatistical Analysis  FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis FY 2013 FY 2014 FY 2015 .docxwhitneyleman54422
 
캐피탈 검토보고서 En
캐피탈 검토보고서 En캐피탈 검토보고서 En
캐피탈 검토보고서 EnHyundai Finance
 

Similar to Accounts (20)

Sa fy12-annual-finstatement12
Sa fy12-annual-finstatement12Sa fy12-annual-finstatement12
Sa fy12-annual-finstatement12
 
Zenith bank annual report 2018
Zenith bank annual report 2018Zenith bank annual report 2018
Zenith bank annual report 2018
 
Pci fs 2012
Pci fs 2012Pci fs 2012
Pci fs 2012
 
Review reports 1 q2017 en
Review reports 1 q2017 enReview reports 1 q2017 en
Review reports 1 q2017 en
 
Zenith bank annual report 2015
Zenith bank annual report 2015Zenith bank annual report 2015
Zenith bank annual report 2015
 
PLDT Financial Statements (2013-2015)
PLDT Financial Statements (2013-2015)PLDT Financial Statements (2013-2015)
PLDT Financial Statements (2013-2015)
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
 
2016 영문 감사보고서 en
2016 영문 감사보고서  en2016 영문 감사보고서  en
2016 영문 감사보고서 en
 
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...
Startup4Chinese #14: Hate financial trouble? Guidelines for non-finance backg...
 
OXYS Investor Presentation
OXYS Investor PresentationOXYS Investor Presentation
OXYS Investor Presentation
 
AnnualReport_2020-21.aspx.pdf
AnnualReport_2020-21.aspx.pdfAnnualReport_2020-21.aspx.pdf
AnnualReport_2020-21.aspx.pdf
 
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docx
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docxCONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docx
CONSOLIDATED FINANCIAL STATEMENTS OFSAMSUNG ELECTRONICS CO.docx
 
캐 재무제표 2015_영
캐 재무제표 2015_영캐 재무제표 2015_영
캐 재무제표 2015_영
 
1Q21_Audit_EN.pdf
1Q21_Audit_EN.pdf1Q21_Audit_EN.pdf
1Q21_Audit_EN.pdf
 
2016년 1분기 검토보고서 en
2016년 1분기 검토보고서  en2016년 1분기 검토보고서  en
2016년 1분기 검토보고서 en
 
Consolidate december-2012
Consolidate december-2012Consolidate december-2012
Consolidate december-2012
 
2016 audited financials
2016 audited financials2016 audited financials
2016 audited financials
 
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis  FY 2013 FY 2014 FY 2015 .docxStatistical Analysis  FY 2013 FY 2014 FY 2015 .docx
Statistical Analysis FY 2013 FY 2014 FY 2015 .docx
 
캐피탈 검토보고서 En
캐피탈 검토보고서 En캐피탈 검토보고서 En
캐피탈 검토보고서 En
 
2014 FFIN Annual Meeting Presentation
2014 FFIN Annual Meeting Presentation2014 FFIN Annual Meeting Presentation
2014 FFIN Annual Meeting Presentation
 

Accounts

  • 1. INFOSYS LIMITED Balance Sheet as at March 31, Note EQUITY AND LIABILITIES SHAREHOLDERS' FUNDS Share capital 2.1 Reserves and surplus 2.2 NON-CURRENT LIABILITIES Deferred tax liabilities (net) 2.3 Other long-term liabilities 2.4 CURRENT LIABILITIES Trade payables 2.5 Other current liabilities 2.6 Short-term provisions 2.7 ASSETS NON-CURRENT ASSETS Fixed assets Tangible assets 2.8 Intangible assets 2.8 Capital work-in-progress Non-current investments 2.10 Deferred tax assets (net) 2.3 Long-term loans and advances 2.11 Other non-current assets 2.12 CURRENT ASSETS Current investments 2.10 Trade receivables 2.13 Cash and cash equivalents 2.14 Short-term loans and advances 2.15 SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS 1 & 2 2013 287 35,772 36,059 56 120 176 178 2,827 3,788 6,793 43,028 4,425 28 1,135 5,588 2,764 378 1,529 31 10,290 1,580 6,365 20,401 4,392 32,738 43,028 in ` crore 2012 287 29,470 29,757 - 21 21 68 2,365 3,604 6,037 35,815 4,045 16 588 4,649
  • 2. 1,068 189 1,431 13 7,350 341 5,404 19,557 3,163 28,465 35,815 Deepak M. Satwalekar Director R.Seshasayee Director V. Balakrishnan Director N.R. Ravikrishnan Company Secretary As per our report at tached for BSR&Co. Chartered Accountants Firm's Regist rat ion Number:101248W Nat rajh Ramakrishna Partner Membership No. 32815 K.V.Kamath Chairman Dr. Omkar Goswami Director Ann M. Fudge Director Ashok Vemuri Director S. Gopalakrishnan Execut ive Co-Chairman David L. Boyles Director Ravi Venkatesan Director
  • 3. B. G. Srinivas Director S. D. Shibulal Bangalore April 12, 2013 Chief Execut ive Officer and Managing Director Prof. Jeffrey S. Lehman Director Srinath Batni Director Rajiv Bansal Chief Financial Officer 1 INFOSYS LIMITED Statement of Profit and Loss for the Income from software services and products Other income Total revenue Expenses Employee benefit expenses Deferred consideration pertaining to acquisit ion Cost of technical sub-contractors Travel expenses Cost of software packages and others Communication expenses Professional charges Depreciation and amortisation expense Other expenses Total expenses PROFIT BEFORE EXCEPTIONAL ITEM AND TAX Dividend income PROFIT BEFORE TAX Tax expense: Current tax Deferred tax PROFIT FOR THE PERIOD EARNINGS PER EQUITY SHARE Equity shares of par value `5/- each Before Exceptional item Basic Diluted After Exceptional item Basic Diluted
  • 4. Number of shares used in comput ing earnings per share Basic Diluted SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS As per our report at tached for BSR&Co. Chartered Accountants Firm's Regist rat ion Number : 101248W Note 2.16 2.17 2.18 2.10.1 2.18 2.18 2.18 2.18 2.8 2.18 2.36 2.19 2.19 in ` crore, except per share data Quarter ended March 31, Year ended March 31, 2013 9,329 647 9,976 5,199 50 524 270 182 70 117 256 286 6,954 3,022 - 3,022 738 (21) 2,305 40.14 40.14 40.14 40.14 2012 2013 2012 31,254 1,829 33,083 15,473 - 2,483 944 625 203 437 794 1,028 21,987 11,096 578 11,674 3,147 57 8,470 139.07 139.06
  • 5. 147.51 147.50 8,183 609 8,792 4,051 - 656 231 182 53 85 204 219 5,681 3,111 578 3,689 909 21 2,759 39.61 39.61 48.05 48.05 36,765 2,215 38,980 19,932 85 1,731 1,281 734 289 504 956 1,194 26,706 12,274 83 12,357 3,361 (120) 9,116 157.55 157.55 158.76 158.76 2.31 1&2 S. Gopalakrishnan Execut ive Co-Chairman David L. Boyles Director Ravi Venkatesan Director B. G. Srinivas Director 57,42,36,166 57,42,25,771 57,42,32,838 57,41,99,094 57,42,36,166 57,42,33,173 57,42,33,691 57,42,29,742 Nat rajh Ramakrishna Partner Membership No. 32815 K.V.Kamath
  • 6. Chairman Dr. Omkar Goswami Director Ann M. Fudge Director Ashok Vemuri Director S. D. Shibulal Chief Execut ive Officer and Managing Director Prof. Jeffrey S. Lehman Director Srinath Batni Director Rajiv Bansal Chief Financial Officer Deepak M. Satwalekar Director R.Seshasayee Director V. Balakrishnan Director N.R. Ravikrishnan Company Secretary Bangalore April 12, 2013 2 INFOSYS LIMITED Cash Flow Statement for the CASH FLOWS FROM OPERATING ACTIVITIES Profit before tax and exceptional item Adjustments to reconcile profit before tax to cash provided by operating activities Depreciation and amortisation expense Payable for acquisition of business Interest and dividend income Loss/(Profit) on sale of tangible assets Effect of exchange differences on translation of assets and liabilities Effect of exchange differences on translation of foreign currency cash and cash equivalents
  • 7. Changes in assets and liabilities Trade receivables Loans and advances and other assets Liabilities and provisions Income taxes paid NET CASH GENERATED BY OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Payment towards capital expenditure Investments in subsidiaries Investment in other investments Disposal of other investments Interest and dividend received CASH FLOWS FROM INVESTING ACTIVITIES BEFORE EXCEPTIONAL ITEM Dividend received NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of share capital on exercise of stock options Loan given to subsidiary Dividends paid including residual dividend Dividend tax paid NET CASH USED IN FINANCING ACTIVITIES Effect of exchange differences on translation of foreign currency cash and cash equivalents NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS Add: Bank balances taken over from Infosys Consulting Inc., USA (refer to note 2.25) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS Note Year ended March 31, 2013 12,274 956 85 (1,931) - 15 (45) (961) (997) 690 10,086 (3,144) 6,942 (1,847) (1,384) (1,883) 336 1,871 (2,907) 83 (2,824) 1 (184) (2,698) (438) (3,319) 45 844 - 19,557 20,401 in ` crore 2012 11,096
  • 8. 794 - (1,720) (2) 19 (60) (1,180) (819) 671 8,799 (2,938) 5,861 (1,296) (104) (2,796) 2,574 1,703 81 578 659 6 35 (2,012) (327) (2,298) 60 4,282 110 15,165 19,557 As per our report attached for BSR&Co. Chartered Accountants Firm's Registration Number : 101248W 2.35.1 2.35.2 2.35.3 2.35.4 2.35.5 2.35.6 2.35.7 2.35.7 2.35.8 2.36 2.35.9 1 & 2